Study Tests Whether a Standardized LVR Performed With the Blue Egg Device Improves Cardiopulmonary Exercise Capacity

Inclusion Criteria: * Be 18 years of age or older * Have symptomatic heart failure consistent with NYHA Class III or IV * Have been treated, in the opinion of the Principal Investigator, for at least 12 weeks with an optimized pharmacological regimen, including no substantial dosage titration for the last 4 weeks. This will typically mean that the subject has had (unless intolerant) appropriate doses of angiotensin-converting enzyme (ACE) inhibitors, beta-blockers (β-blockers) and/or aldosterone inhibitors and diuretics. * Have a dilated left ventricular (LV) with an LV end-systolic volume index (LVESVI) of 60 ml/m² and an akinetic or dyskinetic anterior wall * Have an LV ejection fraction less than or equal to 35% * Have an MVO2 of equal to or greater than 10, but equal to or less than 16 ml O2/min/kg * Have demonstrated myocardial infarction without viability on a dobutamine stress echocardiogram in a region considered for surgery. Alternatively, have demonstrated the same physiological feature with gadolinium/magnetic resonance imaging (MRI) procedures or other sophisticated methodology for viability assessment. * Agree to be compliant with the study protocol and willing and able to return for follow-up Exclusion Criteria: * Have had a myocardial infarction within 90 days of consent * Be inotrope or intra-aortic balloon pump (IABP) dependent * Require, in the judgment of the Principal Investigator, cardiac surgery that cannot be deferred for 6 months, such as subjects with: * left main coronary artery disease * intractable ventricular arrhythmias * Canadian Cardiovascular Society Angina Class III or IV symptoms * aortic stenosis or insufficiency requiring replacement * 3+ or 4+ mitral regurgitation * Have any comorbid medical condition that is a contraindication to cardiac surgery (e.g., renal failure, coagulopathy, severe chronic obstructive pulmonary disease \[COPD\], cerebrovascular accident \[CVA\], prior stroke, known malignancy etc.) * Have congestive heart failure (CHF) due to a cause other than ischemic cardiomyopathy * Have a history of radiation therapy to the chest or mediastinum * Have exercise tolerance limited by a condition other than heart failure * Be unable to perform cardiopulmonary stress test * Have a history of alcohol abuse, drug addiction, or other psychosocial condition that would preclude successful participation or realization of benefit from the trial in the opinion of the Principal Investigator. * Be a female of child-bearing age who is pregnant or does not agree to use standard methods of birth control. * Carry a diagnosis of an illness other than CHF with life expectancy less than 12 months. * Participating in another trial (other than non-therapeutic or interventional observation) within the last 30 days or less than 60 days after completion of a heart failure drug trial. * Biventricular pacemaker implantation and/or activation within the past 60 days * Percutaneous coronary intervention (PCI) with coronary revascularization within the last 60 days. * More than one prior sternotomy